Crown Equity Holdings Inc. (OTCPK:CRWE)
CRWE has issued a letter to its shareholders. You can find the Company's operational update at http://crwepressrelease.com/2014/10/crown-equity-holdings-inc-issues-letter-to-shareholders/ or click on the picture below:
CRWE is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of website communities, which business model is based on selling advertising to businesses targeting both locally and nationally
CRWE has included the City of Jamestown, NY ( www.jamestown.ny.crwe-pr.com ) to the CRWE Network.
Jamestown, NY, an economically sound and vibrant community serving as the industrial, commercial, financial and recreational hub of Southwestern New York, and with an estimated population in 2013 (U.S. Census Bureau) of approximately 30,737, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1400th community website in the U.S., associated with 3282 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.
CRWE and PolarWeb Media, LLC reported a Joint Venture agreement to engage in increasing web traffic to selected websites.
CRWE will receive 50% of the revenues generated by PolarWeb Media through the use of the CRWE Network, with PolarWeb Media having the remaining 50%. PolarWeb Media, LLC will focus on driving traffic and generating ad revenues.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
GW Pharmaceuticals plc (NASDAQ:GWPH)
Keep a close eye on GWPH. The company had its Research and Development Day in New York City, NY.
Brokerage firm Piper Jaffray said it has "substantially greater" confidence in the outlook for Epidiolex for seizures and related indications after attending GWPH's analyst day. Piper restated their Overweight rating on the stock and said its price target of $147.00 per share of the company may be conservative since it may underestimate the seizure opportunity and includes no assumptions for other pediatric conditions GWPH highlighted at the event (Source here).
At its Research and Development Day, GWPH reported preliminary topline results from a Phase 2a ulcerative colitis trial, a 10-week randomized, double-blind, placebo controlled study of GWP42003 extract, which features Cannabidiol (NYSE:CBD) as the primary cannabinoid and which also contains Tetrahyrdocannabinol (NYSE:THC) and other cannabinoid and non-cannabinoid components.
According to Chief Investigator of the study, the results provide promising evidence that GWP42003 may produce clinically relevant improvement in the severity of ulcerative colitis compared with placebo, in patients who complete a course of treatment
GWPH also announced new physician reports of efficacy and safety associated with the Epidiolex(NYSE:R) "expanded access" studies.
The patients suffer from a range of treatment-resistant epilepsies. Many have extreme and rare forms of epilepsy including several patients with major congenital structural brain abnormalities.
Physician reports show promising signals of efficacy and safety consistent with previously disclosed data, as well as maintenance of clinical effect beyond 12 weeks and high retention rate
Dr. Elizabeth Thiele, Director of the Pediatric Epilepsy Program at Massachusetts General Hospital and Harvard Professor of Neurology, believes that GWPH's Epidiolex has the potential to be an important advance in treatment for these treatment-resistant children and will likely have a significant role as a future therapy.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 26 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world.
GWPH has a deep pipeline of additional cannabinoid product candidates, including Epidiolex(R) in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GWPH's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia.
Ann Inc. (NYSE:ANN)
ANN reported that it has entered into a non-disclosure agreement with Golden Gate Capital providing for the sharing of certain non-public information with Golden Gate.
ANN said that subsequent to Golden Gate's filing of a 13D on March 20, 2014, it has been engaged in a collaborative, constructive dialogue with Golden Gate. ANN and Golden Gate believe that, given Golden Gate's expertise in specialty retail and the positive interactions between the companies to date, it would be beneficial to continue discussions on a more detailed basis.
ANN is the parent Company of Ann Taylor and LOFT, two of the leading women's specialty retail fashion brands in North America. As of August 2, 2014, ANN operated 1,040 Ann Taylor, Ann Taylor Factory, LOFT and LOFT Outlet stores in 47 states, the District of Columbia, Puerto Rico and Canada.
Disclaimer: The assembled information disseminated by CRWE-PR Finance is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Crown Equity Holdings Inc. (OTCPK:CRWE) will receive 50% of the revenues generated by PolarWeb Media through the use of CRWE's sites, with PolarWeb Media having the remaining 50%. Entire Disclaimer at www.finance.crwe-pr.com/disclaimer
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.